UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM 8-K

CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):

July 16, 2014 (July 16, 2014)

HARRIS & HARRIS GROUP, INC.

(Exact name of registrant as specified in its charter)

New York (State or other jurisdiction of incorporation) **0-11576** (Commission File Number) 13-3119827 (IRS Employer Identification No.)

1450 Broadway New York, New York 10018

(Address of principal executive offices and zip code)

(212) 582-0900

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

□ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

□ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

□ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

□ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01. Other Events.

On July 16, 2014, Harris & Harris Group, Inc. (the "Company") announced its investment in UberSeq, Inc. The Company invested \$500,000 in UberSeq's Series Seed Financing in June of 2014. UberSeq is a translational genomics company originated from Stanford University. The Company's press release is attached hereto as Exhibit 99.1.

Item 9.01. Financial Statements and Exhibits.

- (a) Not applicable.
- (b) Not applicable.
- (c) Not applicable.
- (d) Exhibits.

Exhibit No. Description

99.1 Press Release dated July 16, 2014

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: July 16, 2014

HARRIS & HARRIS GROUP, INC.

By: <u>/s/ Douglas W. Jamison</u> Douglas W. Jamison Chief Executive Officer

EXHIBIT INDEX

Exhibit No.Description99.1Press Release dated July 16, 2014



Harris & Harris Group Invests in UberSeq, Inc.

NEW YORK, NY – July 16, 2014 – Harris & Harris Group, Inc. (Nasdaq:TINY), an investor in transformative companies enabled by disruptive science, announced today its investment in UberSeq, Inc. Harris & Harris Group invested \$500,000 in UberSeq's Series Seed Financing in June of 2014. UberSeq is a translational genomics company that originated from Stanford University.

"Personalized genomics are now coming through a rapid evolution, akin to that of the semiconductor industry 30 years ago. We believe that this ongoing shift should allow well positioned players like UberSeq to benefit disproportionally from the industry's transformation," said Alexei Andreev, a Managing Director of Harris & Harris Group. "UberSeq is another example of Harris & Harris Group being actively involved in the launching and building of exciting BIOLOGY+ companies addressing real market needs," said Douglas Jamison, CEO of Harris & Harris Group. "Look for us to continue to make these types of investments."

About Harris & Harris Group

Harris & Harris Group is a publicly traded venture capital firm that is also a business development company. Detailed information about Harris & Harris Group and its holdings can be found on its website at <u>www.HHVC.com</u>, on Facebook at <u>www.facebook.com/harrisharrisvc</u> and by following on Twitter <u>@harrisandharrisgroup</u>.

This press release may contain statements of a forward-looking nature relating to future events. These forward-looking statements are subject to the inherent uncertainties in predicting future results and conditions. These statements reflect the Company's current beliefs, and a number of important factors could cause actual results to differ materially from those expressed in this press release. Please see the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2013, as well as subsequent filings, filed with the Securities and Exchange Commission for a more detailed discussion of the risks and uncertainties associated with the Company's business, including, but not limited to, the risks and uncertainties associated with venture capital investing and other significant factors that could affect the Company's actual results. Except as otherwise required by Federal securities laws, the Company undertakes no obligation to update or revise these forward-looking statements to reflect new events or uncertainties. The references to the websites www.HHVC.com and www.Facebook.com have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Harris & Harris Group is not responsible for the contents of third party websites.

Press contact

Jessica Attanasio Associate Vice President Gregory FCA Jessica@GregoryFCA.com 610-228-2112